MiNK Therapeutics, Inc. financial data

Symbol
INKT on Nasdaq
Location
149 Fifth Avenue, Suite 500, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 55 % -14.1%
Return On Equity 61.7 % -18.8%
Return On Assets -180 % +4.76%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.69M shares -88.1%
Common Stock, Shares, Outstanding 3.96M shares +14.5%
Entity Public Float 13.9M USD -32.2%
Common Stock, Value, Issued 46 USD -88.4%
Weighted Average Number of Shares Outstanding, Basic 4.44M shares +12.4%
Weighted Average Number of Shares Outstanding, Diluted 4.44M shares +12.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.65M USD -31.4%
General and Administrative Expense 5.78M USD +1.42%
Operating Income (Loss) -12.4M USD +12.9%
Net Income (Loss) Attributable to Parent -12.4M USD +10.3%
Earnings Per Share, Basic -2 USD/shares +64.2%
Earnings Per Share, Diluted -2 USD/shares +64.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.3M USD +126%
Other Assets, Current 55.2K USD -9.71%
Assets, Current 14.5M USD +121%
Property, Plant and Equipment, Net 429K USD -46.3%
Assets 15M USD +103%
Accounts Payable, Current 3.69M USD +56.4%
Accrued Liabilities, Current 1.26M USD -52.5%
Liabilities, Current 13.4M USD +81.6%
Other Liabilities, Noncurrent 0 USD -100%
Accumulated Other Comprehensive Income (Loss), Net of Tax -692K USD -2.87%
Retained Earnings (Accumulated Deficit) -154M USD -8.72%
Stockholders' Equity Attributable to Parent -13.5M USD +23%
Liabilities and Equity 15M USD +103%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.34M USD +47.3%
Net Cash Provided by (Used in) Financing Activities 5.01M USD
Net Cash Provided by (Used in) Investing Activities -13.5K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 4.6M shares -88.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.34M USD -155%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.3M USD +126%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.68K USD -28.1%
Deferred Tax Assets, Valuation Allowance 31M USD +4.34%
Deferred Tax Assets, Gross 31M USD +4.34%
Depreciation 50.8K USD -5.7%
Payments to Acquire Property, Plant, and Equipment 13.5K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -12.4M USD +12.5%
Property, Plant and Equipment, Gross 1.26M USD -13.2%
Preferred Stock, Shares Authorized 5M shares 0%
Share-based Payment Arrangement, Expense 2.48M USD -29.7%
Interest Expense -110K USD +10.7%